Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting September 8, 2026
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg July 28, 2026
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June May 26, 2026
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults May 21, 2026
